Surgical Treatment of Hydatid Liver Disease

NCT ID: NCT05989516

Last Updated: 2023-08-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

72 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2023-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this observational study is to show that cyst extraction with pericyst reduction and omentopexy is a suitable treatment for liver hydatid disease caused by E.Granulossus with a low rate of complication and recurrence.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hydatid Cyst, Hepatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* hydatid liver disease

Exclusion Criteria

* hydatid disease present outside the liver
Minimum Eligible Age

16 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital for Surgical Diseases St. Naum Ohridsk i- Skopje

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Elena Zafirovikj

Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Elena Zafirovikj, MD

Role: PRINCIPAL_INVESTIGATOR

UHSD St. Naum Ohridski

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Elena Zafirovikj

Skopje, , North Macedonia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

North Macedonia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

001/0/2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Octreotide in Severe Polycystic Liver Disease
NCT00426153 COMPLETED PHASE2/PHASE3
Faecal Microbiota Transplantation for Liver Cirrhosis
NCT04932577 RECRUITING PHASE2/PHASE3
Hepatocyte Matrix Implant Study
NCT00935454 UNKNOWN PHASE1